HLP003 Phase 3 Depression Results: Half of Patients Reach Remission by Week 6
Helus Pharma deuterated psilocin HLP003 beat placebo by 7.6 MADRS points in Phase 3 APPROACH, with 50.9% remission at week 6. Data, caveats, timeline.
Helus Pharma deuterated psilocin HLP003 beat placebo by 7.6 MADRS points in Phase 3 APPROACH, with 50.9% remission at week 6. Data, caveats, timeline.